Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea
- Authors
- Kim, Ji Yoon; Kim, Kyoung Jin; Bae, Jae hyun; Kim, Joo Hyung; Kim, Nam Hoon; Kim, Hee Young; Kim, Hoon Yub; Baek, Seung-Kuk; Kim, Sin Gon; Jung, Kwang Yoon; Kim, Kyeong Jin
- Issue Date
- Nov-2021
- Publisher
- 대한갑상선학회
- Keywords
- Papillary thyroid microcarcinoma; BRAF V600E mutation; Active surveillance; Tumor recurrence
- Citation
- International Journal of Thyroidology, v.14, no.2, pp 135 - 142
- Pages
- 8
- Indexed
- KCI
- Journal Title
- International Journal of Thyroidology
- Volume
- 14
- Number
- 2
- Start Page
- 135
- End Page
- 142
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/55143
- DOI
- 10.11106/ijt.2021.14.2.135
- ISSN
- 2384-3799
2466-1899
- Abstract
- Background and Objectives: The clinical implications of the BRAF V600E mutation in papillary thyroid microcarcinoma (PTMC), defined as ≤1.0 cm of tumor size, remain controversial. We investigated the association between the BRAF V600E mutation and PTMC recurrence in a retrospective cohort of patients with thyroid cancer.
Materials and Methods: This study included 2319 patients with PTMC (median age, 50 years [interquartile range (IQR), 41-57 years]) who underwent thyroid surgery from 2010 to 2019 at a single tertiary medical center. The median follow-up time was 75 months (IQR, 30-98 months). Tumor recurrence was confirmed by histological, cytological, radiographic, and biochemical criteria, combined with persistent and recurrent disease.
Results: A total of 60.2% (1395/2319) patients with PTMC had the BRAF V600E mutation. The tumor recurrence rate was 2.1% (19/924) in BRAF mutation-negative patients and 2.9% (41/1395) in BRAF mutation-positive patients, with a hazard ratio (HR) of 1.05 (95% confidence interval [CI], 0.61-1.84) after adjusting for clinicopathological risk factors. Similar results were found in patients with high-risk PTMC (adjusted HR, 1.09; 95% CI, 0.56-2.11) who had lymph node metastasis (LNM), extrathyroidal extension (ETE), or distant metastasis (DM) at diagnosis and in patients with low-risk PTMC (adjusted HR, 1.00; 95% CI, 0.35-2.83) who had no LNM, ETE, or DM.
Conclusion: The finding that the BRAF V600E mutation was not associated with tumor recurrence in our cohort of Korean patients with PTMC, especially in patients with low-risk PTMC, suggests that its value in the prediction of disease progression is limited.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Otorhinolaryngology-Head and Neck Surgery > 1. Journal Articles
- 2. Clinical Science > Department of Anesthesiology and Pain Medicine > 1. Journal Articles
- 2. Clinical Science > Department of Endocrinology and Metabolism > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.